Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bruce Diebold

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Respiratory Cell and Molecular Biology|June 11, 2024
Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical StudiesSoyoung Hwang, Wongil Lee, Dashnamoorthy Ravi, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2011
3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitorDavid A Scott, Les A Dakin, David J Del Valle, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2014
Towards the next generation of dual Bcl-2/Bcl-xL inhibitorsJeffrey G Varnes, Thomas Gero, Shan Huang, et al.
Bioorganic & Medicinal Chemistry Letters|July 12, 2013
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507David A Scott, Les A Dakin, Kevin Daly, et al.
Journal of Medicinal Chemistry|January 24, 2020
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 InhibitorJustin A Caravella, Jian Lin, R Bruce Diebold, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) InhibitorsJian Lin, Wei Lu, Justin A Caravella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Respiratory Cell and Molecular Biology|June 11, 2024
Novel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical StudiesSoyoung Hwang, Wongil Lee, Dashnamoorthy Ravi, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2011
3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitorDavid A Scott, Les A Dakin, David J Del Valle, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2014
Towards the next generation of dual Bcl-2/Bcl-xL inhibitorsJeffrey G Varnes, Thomas Gero, Shan Huang, et al.
Bioorganic & Medicinal Chemistry Letters|July 12, 2013
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507David A Scott, Les A Dakin, Kevin Daly, et al.
Journal of Medicinal Chemistry|January 24, 2020
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 InhibitorJustin A Caravella, Jian Lin, R Bruce Diebold, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) InhibitorsJian Lin, Wei Lu, Justin A Caravella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Pageof 1